Breakthrough in MS treatment

Research

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Une équipe dirigée par un chercheur de l’INM obtient 6,1 M$ pour étudier la SP

Other News

Douglas Arnold, un chercheur de l’INM, a obtenu une subvention de 6,1 millions de dollars pour mener une étude sur la sclérose en plaques progressive.

$6.1 million for MNI-led multiple sclerosis study

Other News

A project led by Dr. Douglas Arnold, a researcher at the MNI, has been awarded $6.1 million to study progressive multiple sclerosis.